Management ChangeMay 7, 2026, 04:42 PM
STERIS Appoints Pierre Boulud to Board; Richard Breeden Retires
AI Summary
STERIS plc announced changes to its Board of Directors. Richard C. Breeden will retire and not seek re-election after 18 years of service. Concurrently, the Board increased its size from nine to ten members and appointed Pierre Boulud as a new director, effective May 5, 2026. Mr. Boulud, currently the CEO of bioMérieux, brings extensive leadership and operational experience from the biotechnology and pharmaceutical sectors.
Key Highlights
- Richard C. Breeden will not stand for re-election to the Board of Directors after 18 years of service.
- STERIS plc's Board of Directors increased its size from nine to ten members.
- Pierre Boulud was appointed as a new director, effective May 5, 2026.
- Mr. Boulud is the Chief Executive Officer of bioMérieux and previously served as COO.
- He will receive a prorated fee of $76,989 in career restricted stock units for the remainder of the 2025-26 term.
Price Impact
More from STE